MAP2K7 and melanoma: Among the selective serine/threonine kinase inhibitors, BRAF inhibitors (Vemurafenib and Dabrafenib) and MEK inhibitors (Trametinib and Cobimetinib) are widely used in clinical practice for the treatment of mutated BRAFV600E melanomas, providing significant improvement in survival rates (Robert et al., 2015).